Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydrogel-CXCL9 mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
**Hydrogel-CXCL9 mRNA vaccine** is a preclinical, subcutaneously administered glioblastoma immunotherapy developed at the University of Florida. Also called the hydrogel-chemokine-mRNA vaccine, it co-formulates total tumor-derived mRNA in lipid nanoparticles with the chemokine CXCL9 in a polyethylene glycol hydrogel. The CXCL9-containing depot recruits dendritic cells, natural killer cells, and T cells; recruited antigen-presenting cells take up and express the tumor mRNA payload, promoting tumor-antigen-specific CD8 T-cell responses. In syngeneic murine glioma models, subcutaneous administration produced immune-cell recruitment, tumor-microenvironment reprogramming, and survival benefit; activity was associated with intratumoral CCL4 induction and CD4 T-cell-dependent signaling. ([academic.oup.com](https://academic.oup.com/neuro-oncology/article-abstract/23/Supplement_6/vi96/6426893))
- Other names
- HCM vaccinehydrogel-CXCL9 mRNA vaccinehydrogel-CXCL-9 mRNA vaccinehydrogel-CXCL 9 mRNA vaccinehydrogel-CXCL9 vaccinehydrogel-CXCL-9 vaccinehydrogel-CXCL 9 vaccinehydrogel-CXCL9-mRNA vaccinehydrogel-CXCL-9-mRNA vaccinehydrogel-CXCL 9-mRNA vaccineHydrogel-Chemokine-mRNA vaccine
02
Targets
CCR3 (C-C chemokine receptor type 3)
Beyond the preview
Go deeper on hydrogel-CXCL9 mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydrogel-CXCL9 mRNA vaccine.